Full text is available at the source.
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Cancer immunotherapy using antibodies targeting the PD-1 and PD-L1 immune control pathway
AI simplified
Abstract
Overexpression of PD-L1 and PD-1 is associated with poor disease outcomes in some human cancers.
- The PD-1 receptor and its ligands, PD-L1 and PD-L2, are key players in T cell regulation and exhaustion.
- Blocking the PD-1/PD-L1 pathway with monoclonal antibodies has been shown to enhance T cell functions in cancer immunotherapy.
- Clinical trials have demonstrated notable response rates for PD-1 and PD-L1 antibodies in melanoma, non-small-cell lung cancer, renal cell carcinoma, and bladder cancer.
- Further research is necessary to understand the reasons behind varying response rates and to identify potential biomarkers for treatment response.
- Development of small-molecule inhibitors and combination therapies is also an area of ongoing investigation.
AI simplified